The mRNA levels of the lipid β-oxidation pathway involving PPARα and its downstream targets, CPT1A and ACOX1, were inhibited in the NAFLD model compared to the control group (Fig. 7A, B, C, p < 0.05). The gene discussed is CPT1A; the disease is metabolic dysfunction-associated steatotic liver disease.